Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of CHEK opened at $1.15 on Thursday. Check-Cap has a 12 month low of $1.12 and a 12 month high of $3.94. The stock’s 50 day moving average is $1.62 and its two-hundred day moving average is $1.96. The firm has a market cap of $6.73 million, a P/E ratio of -0.38 and a beta of 0.36.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.